NCT04318145 - Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2023

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

PL-3994 Aqueous Intravenous Solution Dose Ascention

Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion

DRUG

PL-3994 Aqueous Intravenous Solution Single Dose

Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion

Trial Locations (1)

RECRUITING

Northwestern University, Evanston